India and the United States strengthen cooperation to disrupt transnational drug trafficking networks and reduce the flow of synthetic narcotics and the chemicals used to make them. A readout from the White House says the countries discuss intelligence sharing, coordinated law-enforcement efforts, and safeguards for pharmaceutical supply chains, alongside steps to address emerging trafficking threats and reduce drug demand.
The cooperation is framed around the second meeting of the India–U.S. Drug Policy Executive Working Group in New Delhi on November 2–3, 2026. India’s Narcotics Control Bureau (NCB), under the Ministry of Home Affairs, hosts the talks; the American side is led by the White House Office of National Drug Control Policy (ONDCP). The reported focus includes targeting illegal supply chains for chemical precursors and moving from commitments to operational results.
Across outlets, the core details match: the meeting location and dates, the involvement of NCB and ONDCP, and the emphasis on synthetic drugs, precursor diversion, and network-focused enforcement. Differences mainly lie in how prominently they highlight cartels and “crackdown” language versus broader cooperation and demand-reduction themes.
